Mucormycosis: a scavenger for patients with COVID-19 infection with hyperglycaemia
Introduction: The study aims to find the incidence of diabetes in post-COVID-19 patients with mucormycosis as there was a significant rise in cases of mucormycosis in India due to the use of steroids and India being the diabetic capital of the world. Materials and methods: This prospective cross-sectional study was conducted with 50 mucormycosis patients who had a history positive for COVID 19 in the recent past and had been treated for the same and were admitted to the mucor ward in Dr D.Y.Patil medical college and were positive for mucormycosis on fungal culture. Their HbA1C, fasting blood sugars, and urine ketone were evaluated on admission. Results: All 50 (100%) patients were diabetic, out of which 23 (46%) were newly diagnosed while 27 (54%) were known diabetic. Males were more affected than females almost three times. About 88% of patients had deranged fasting blood sugars, and 5 had diabetic ketoacidosis. Conclusion: Post-COVID patients who have received corticosteroids and are known diabetic must be warned about the alarming symptoms and counselled to monitor their blood sugars and HbA1C levels regularly..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
International Journal of Medical Reviews and Case Reports - 6(2022), 10, Seite 7-9 |
| Sprache: |
Englisch ; Portugiesisch |
|---|
| Beteiligte Personen: |
Rishikesh Dilip Pawar [VerfasserIn] |
|---|
| Links: |
dx.doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
DOAJ026251175 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ026251175 | ||
| 003 | DE-627 | ||
| 005 | 20230307100243.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ026251175 | ||
| 035 | |a (DE-599)DOAJ360e335c34524ced81434397a5b807a5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a por | ||
| 100 | 0 | |a Rishikesh Dilip Pawar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mucormycosis: a scavenger for patients with COVID-19 infection with hyperglycaemia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Introduction: The study aims to find the incidence of diabetes in post-COVID-19 patients with mucormycosis as there was a significant rise in cases of mucormycosis in India due to the use of steroids and India being the diabetic capital of the world. Materials and methods: This prospective cross-sectional study was conducted with 50 mucormycosis patients who had a history positive for COVID 19 in the recent past and had been treated for the same and were admitted to the mucor ward in Dr D.Y.Patil medical college and were positive for mucormycosis on fungal culture. Their HbA1C, fasting blood sugars, and urine ketone were evaluated on admission. Results: All 50 (100%) patients were diabetic, out of which 23 (46%) were newly diagnosed while 27 (54%) were known diabetic. Males were more affected than females almost three times. About 88% of patients had deranged fasting blood sugars, and 5 had diabetic ketoacidosis. Conclusion: Post-COVID patients who have received corticosteroids and are known diabetic must be warned about the alarming symptoms and counselled to monitor their blood sugars and HbA1C levels regularly. | ||
| 650 | 4 | |a mucormycosis | |
| 650 | 4 | |a hba1c | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a diabetic | |
| 650 | 4 | |a hyperglycaemia | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Nayanna Karodpati |e verfasserin |4 aut | |
| 700 | 0 | |a Vinayak Kuradagi |e verfasserin |4 aut | |
| 700 | 0 | |a Gowtham K |e verfasserin |4 aut | |
| 700 | 0 | |a Tejal Sonar |e verfasserin |4 aut | |
| 700 | 0 | |a Aastha Bhatnagar |e verfasserin |4 aut | |
| 700 | 0 | |a Lakshmi Krishnan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Medical Reviews and Case Reports |d International Sci Ink Press Ltd, 2018 |g 6(2022), 10, Seite 7-9 |w (DE-627)DOAJ000092606 |x 25349821 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2022 |g number:10 |g pages:7-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5455/IJMRCR.172-1642076679 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/360e335c34524ced81434397a5b807a5 |z kostenfrei |
| 856 | 4 | 0 | |u https://mdpub.net/index.php?fulltxt=3511&fulltxtj=172&fulltxtp=172-1642076679.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2534-9821 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2022 |e 10 |h 7-9 | ||